Acticor Biotech Revenue
Biotechnology Research • 
Paris, Île-de-France, France • 11-20 Employees
Acticor Biotech revenue & valuation
| Annual revenue | $2,500,000 |
| Revenue per employee | $193,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $8,000,000 |
| Total funding | $21,600,000 |
Key Contacts at Acticor Biotech
Anouar Sari
Clinical Operations Director
Sirine Bougamra
Medical Director
Philippe Le Berre
Senior Medical Director. Acticor Biotech. Stroke And Cv Thrombosis.
Company overview
| Headquarters | Paris Santé Cochin, 27 rue du Faubourg Saint Jacques, Paris, 75014, FR |
| Phone number | +3319902016 |
| Website | |
| SIC | 873 |
| Keywords | Biotechnology, Stroke, Drug Development, Healthcare, TIA, Stroke, Thrombosis, Monoclonal Antibody, AVC |
| Founded | 2013 |
| Employees | 11-20 |
| Socials |
Acticor Biotech Email Formats
Acticor Biotech uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About Acticor Biotech
Acticor Biotech is a spin-off from Inserm (French National Institute of Health and Medical Research) dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes which account for 80% of all strokes. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less that 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains. This project is based on the academic research from Acticor Biotech founders Dr. M. Jandrot-Perrus and Prof. P. Billiald. It was supported by top institutions including the ANR (The French National Research Agency), the Fondation de France. The project also won the 2012 national prize for innovation in creation & development category from the BPI (French Public Investment Bank, formerly Oseo).
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Acticor Biotech has 9 employees across 3 departments.
Departments
Number of employees
Funding Data
Explore Acticor Biotech's funding history, including investment rounds, total capital raised, and key backers.
Acticor Biotech Tech Stack
Discover the technologies and tools that power Acticor Biotech's digital infrastructure, from frameworks to analytics platforms.
CDN
CDN
JavaScript libraries
Webmail
Ecommerce
Miscellaneous
Security
Miscellaneous
Translation
Page builders
JavaScript libraries
Hosting
Netherlands
United States
Norway
United Kingdom
Frequently asked questions
4.8
40,000 users
